Skip to main content
Aelis Farma logo

Aelis Farma — Investor Relations & Filings

Ticker · AELIS ISIN · FR0014007ZB4 LEI · 8945008D5R6WV7EXRN47 PA Manufacturing
Open in API
Filings indexed 157 across all filing types
Latest filing 2026-01-12 Regulatory Filings
Country FR France
Listing PA AELIS

About Aelis Farma

https://www.aelisfarma.com

Aelis Farma is a clinical-stage biopharmaceutical company that discovers and develops treatments for brain and central nervous system (CNS) disorders. The company has created a new class of drugs called Signaling Specific inhibitors of the CB1 receptor (CB1-SSi). This proprietary mechanism is designed to selectively inhibit the pathological signaling of the CB1 receptor, which is implicated in various brain diseases, while preserving its normal physiological functions and avoiding adverse effects associated with previous CB1-targeting drugs. The company's lead drug candidate, AEF0117, is in development for the treatment of Cannabis Use Disorder (CUD). Its second candidate, AEF0217, is being investigated for the treatment of cognitive deficits, including those associated with Down syndrome.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release issued by Aelis Farma announcing a positive regulatory opinion from the EMA's Pediatric Committee regarding their drug candidate AEF0217. It details the clinical development strategy and the significance of this milestone for the company's pipeline. As it is a corporate announcement regarding regulatory progress and business operations, and does not fit into specific financial reporting categories like 10-K or IR, it is classified as a general regulatory filing/announcement.
2026-01-12 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release issued by Aelis Farma announcing that the European Medicines Agency (EMA) Pediatric Committee (PDCO) has issued a favorable opinion on their Pediatric Investigation Plan (PIP) for the drug AEF0217. It details the regulatory milestone, the clinical development strategy, and the implications for the company's pipeline. As it is a corporate announcement regarding regulatory progress and does not constitute a full financial report, audit, or proxy statement, it falls under the category of general regulatory announcements or corporate news.
2026-01-12 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release from Aelis Farma announcing the regulatory approval of a Phase 2B clinical trial for their drug candidate AEF0217. It details the trial design, regulatory authorization via the EU Clinical Trials Information System (CTIS), and provides context on the company's clinical pipeline and financial runway. This fits the definition of a Regulatory Filing (RNS) as it is a formal corporate announcement regarding regulatory developments and operational updates.
2025-12-02 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release from Aelis Farma announcing the receipt of regulatory approval for a Phase 2B clinical trial of their drug candidate AEF0217. It details the trial design, the regulatory pathway (CTIS), the target population (Down syndrome), and the expected timeline for results. This is a standard corporate announcement regarding clinical trial progress and regulatory milestones, which falls under the 'Regulatory Filings' (RNS) category as it is a general corporate announcement of a significant operational event.
2025-12-02 French
Rapports financiers et d'audit semestriels/examens réduits / Modalités de mise à disposition du rapport financier semestriel
Report Publication Announcement Classification · 100% confidence The document is a press release titled 'Mise à disposition du rapport financier semestriel 2025' (Availability of the 2025 half-year financial report). It explicitly states that the company has made the report available to the public and filed it with the AMF, providing a link to the company's website for consultation. Following the 'Menu vs Meal' rule, since this is a short announcement (under 5,000 characters of core content) notifying the market of the publication of a report rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2025-09-25 French
Half yearly financial reports and audit reports/limited reviews / Terms of availability of the half-yearly financial report
Report Publication Announcement Classification · 100% confidence The document is a short press release (under 5,000 characters of core content) that explicitly announces the availability and filing of the company's 2025 half-year financial report. It directs readers to the company's website to consult the actual report. Per the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA) rather than the report itself.
2025-09-25 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.